Cara Therapeutics - מכפיל EV/Sales CARA

Cara Therapeutics, Inc. (CARA) is accelerating the development of neurological drugs through synergy with global clinics and pharmaceutical behemoths. Business stability ensures the neutrality of the biomedical sector amidst geopolitical conditions. Portfolio diversification in the treatment of chronic itch and pain complements the company's profile. The enterprise value-to-revenue ratio on GURU.Markets reflects the market price of turnover, where the value 0.00 shows the current magnitude.
פילוחי מדדים פיננסיים ומדדי שוק עבור Cara Therapeutics (CARA)

For Cara Therapeutics, Inc. (CARA), which invests in the development of selective kappa-opioid receptor agonists, this indicator serves as a measure of capitalization efficiency relative to generated revenues. By analyzing the company's current enterprise value to revenue, an investor assesses the business accounting for net debt, which allows for the differentiation of temporary asset undervaluation from a systemic liquidity crisis amid large-scale R&D expenditures.